AEON Financials

Income Statement
MetricQ2 2026Q1 2026Q4 2025Q3 2025Q2 2025
Revenue
0
0
0
0
0
Cost of Revenue
0
0
0
0
0
Gross Profit
0
0
0
0
0
Operating Expenses
5.9M
-0.2%
5.9M
+7.7%
5.5M
+121.1%
2.5M
-42.5%
4.3M
R&D
2.9M
+44.4%
2.0M
+26.4%
1.6M
+169.5%
597.0K
-43.9%
1.1M
SG&A
3.0M
-23.4%
3.9M
+0.3%
3.9M
+101.3%
1.9M
-40.7%
3.3M
Operating Income
-5919000
+0.2%
-5933000
-7.7%
-5511000
-121.1%
-2493000
+42.5%
-4338000
EBITDA
-5899000
+0.3%
-5914000
-7.7%
-5491000
-121.9%
-2474000
+42.7%
-4318000
Net Income
-1155000
+90.2%
-11793000
+68.2%
-37137000
-718.4%
-4538000
+31.7%
-6642000
EPS (Basic)
$-0.02
+93.1%
$-0.29
+89.9%
$-2.86
-633.3%
$-0.39
+35.0%
$-0.60
EPS (Diluted)
$-0.02
+93.1%
$-0.29
+89.9%
$-2.86
-633.3%
$-0.39
+35.0%
$-0.60
Shares (Diluted)
50.5M
+24.4%
40.6M
+213.0%
13.0M
+11.5%
11.6M
+4.9%
11.1M
AEON Biopharma (AEON) โ€” Financials